Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jul 2, 2012 (14 years ago)

Carboplatin Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Carboplatin Injection, 10 mg/mL, a) 5 mL multi-dose vials (NDC 61703-339-18) (NDC 61703-360-18, NOVAPLUS), b) 45 mL multi-dose vials (NDC 61703-339-50) (NDC 61703-360-50 NOVAPLUS), Rx only, Hospira, Inc., Lake Forest, IL 60045, Product of Australia

Affected NDCs 61703-0339-18 61703-0339-50 61703-0360-18 61703-0360-50

Compare with the code on your package — it is the most precise check available.

Drug: Carboplatin

Product details

From the FDA NDC directory, for the product codes this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Carboplatin
NDC 61703-0339
10 mg/mL Injection, Solution
Intravenous
Hospira, Inc. Rx
Carboplatin
NDC 61703-0360
10 mg/mL Injection, Solution
Intravenous
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
61703-339-18
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1648-2012 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Carboplatin recalls

See all
Class II · Moderate risk

Carboplatin active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-562-2015
Class II · Moderate risk

CARBOplatin Injection

Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.

Terminated Sterility / contamination Teva Pharmaceuticals USA, Inc. NDC 0703-3249-11 D-928-2013
Class I · High risk

Carboplatin Injection

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Completed Failed specification Hospira Inc. NDC 61703-339-50 D-154-2013

Other recalls by Hospira Inc.

All 2012 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016